Publications...
Our Publications
PM101: A Cyclodextrin-Based Intravenous Formulation of Amiodarone Devoid of Adverse Hemodynamic Effects
This study provides a useful model for the continued search for a safe and effective intravenous amiodarone formulation devoid of the hypotensive risk associated with the current commercial formulation.
Comparison of the Cardiac Electrophysiology and General Toxicology of Two Formulations of Intravenous Amiodarone in Dogs
Intravenous amiodarone (AIV) must be administered slowly after dilution to avoid hypotension, which is due to the cosolvents polysorbate 80 and benzyl alcohol used in its formulation. PM101 is a formulation of amiodarone devoid of these cosolvents, which enables bolus administration. We evaluated any potential toxicity or exaggerated adverse cardiac electrophysiologic effects of PM101 compared with AIV and control.
The Hypotensive Effect of Intravenous Amiodarone is Sustained Throughout the Maintenance Infusion Period
The objective of the present study was to determine whether the maintenance dose of the conventional formulation of intravenous amiodarone was associated with sustained hypotension throughout the dosing period.
Advantages of the Perfused Isolated Rabbit Heart for the Assessment of the Electrophysiologic and Haemodynamic Effects of Drug Candidates
This paradigm acts as a physiologically relevant bridge between purely in vitro assays and costly, resource-intensive whole-animal studies. The model has been used extensively in experimental cardiovascular investigations and it is a widely accepted surrogate for the study of human cardiac function.
